Allergy Therapeutics suffers phase 3 birch allergy jab trial failureUK-based Allergy Therapeutics has suffered a setback after phase 3 results from the B301 trial of its latest Share XAllergy Therapeutics suffers phase 3 birch allergy jab trial failurehttps://pharmaphorum.com/news/allergy-therapeutics-suffers-phase-3-birch-allergy-jab-trial-failure/
UK biotech round-up: Autolus joins CAR-T race, Horizon’s new CRISPR tech, Allergy Therapeutics’ grass gambitThree small, innovative firms demonstrate the diversity and promise of the UK bioscience sector. While there remains uncertainty Share XUK biotech round-up: Autolus joins CAR-T race, Horizon’s new CRISPR tech, Allergy Therapeutics’ grass gambithttps://pharmaphorum.com/views-and-analysis/uk-biotech-roundup/
